Specialized Glioblastoma Models

60+ first-presentation and recurrent primary (PDX) Glioblastoma mouse models that include:

  • MOA-Based filters using selections driven by your drug’s specific mechanism of action and subsequent interrogation
  • Diverse tissue types including fixed tissue for analysis of novel markers
  • Assessment of tumor progression as single agents and in combination with standard therapies via orthotopic primary tumor models
  • Well-established protocols that ensure an extremely high post-surgery survival rate
Gene copy number and expression
profiling
Chemo vulnerability profiles
(standard agents and unapproved agents)
aCGH profiling Subcutaneous or orthotopic implantation
Exome sequencing TMA for target screening available
CpG methylation Panel represents 4 major subtypes of GBM
Endothelial cell markers  

Learn more about our Glioblastoma capabilities.

Contact our experts to help advance your Glioblastoma drug development program with our specialized models and preclinical services.

    Comprehensive
    Preclinical Services

    Regardless of the development question, TD2 has the specialized model you need to move your drug forward. Clients have access to humanized models, induction models, as well as specialty surgical and orthotopic models. We specialize in all areas of oncology and work diligently to understand your therapeutics’ mechanism of action. We match that with clinical development strategies for an efficient path forward.

    • Non-GLP Safety/Tolerability
    • In vitro Pharmacology Assays
    • DMPK/ADME
    • Orthotopic tumor models
    • CAR-T and Adoptive Cell Therapy models
    • Syngeneic mouse models
    • In vivo Optical Imaging

    Get Started

    Work with a team who believes in your research as much as you do.

    Are you ready to start your preclinical Glioblastoma studies? Partner with a collaborative oncology CRO that believes in your treatment as much as you do. Take the first step today and contact our experts.